| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2575752 | The American Journal of Geriatric Pharmacotherapy | 2011 | 5 Pages |
Abstract
Linezolid has monoamine oxidase (MAO) inhibitory properties, and MAO inhibitors have been reported to contribute to hypoglycemia. The use of linezolid in older diabetic patients, especially those patients already taking agents with the potential to cause hypoglycemia, represents an area of concern. Increased comorbidities and polypharmacy in geriatric patients adds to this concern.
Related Topics
Health Sciences
Medicine and Dentistry
Geriatrics and Gerontology
Authors
Timothy MD, Katelyn PharmD, Jeffrey B. MD,